Science Translational Medicine · 2019 · 126 citations · 20 references
Life SciencesBiochemistryCell BiologyCellular MetabolismDialysisMetabolomicsEpithelial-mesenchymal TransitionEpithelial-to-mesenchymal TransitionFibrosisGlycolysis RegulationMetabolic ReprogrammingPeritoneal DialysisFibrotic ChangeFibrotic Tissue RemodelingMesenchymal TransitionMetabolic State HeterogeneityMitochondrial Respiration ControlMitochondrial Respiration InhibitionMitochondrial Respiration SuppressionPeritoneal Fibrosis
Progressive peritoneal fibrosis affects patients receiving peritoneal dialysis (PD) and has no reliable treatment. The mechanisms that initiate and sustain peritoneal fibrosis remain incompletely elucidated. To overcome these problems, we developed a strategy that prevents peritoneal fibrosis by suppressing PD-stimulated mesothelial-to-mesenchymal transition (MMT). We evaluated single-cell transcriptomes of mesothelial cells obtained from normal peritoneal biopsy and effluent from PD-treated patients. In cells undergoing MMT, we found cellular heterogeneity and intermediate transition states associated with up-regulation of enzymes involved in glycolysis. The expression of glycolytic enzymes was correlated with the development of MMT. Using gene expression profiling and metabolomics analyses, we confirmed that PD fluid induces metabolic reprogramming, characterized as hyperglycolysis, in mouse peritoneum. We found that transforming growth factor β1 (TGF-β1) can substitute for PD fluid to stimulate hyperglycolysis, suppressing mitochondrial respiration in mesothelial cells. Blockade of hyperglycolysis with 2-deoxyglucose (2-DG) inhibited TGF-β1-induced profibrotic cellular phenotype and peritoneal fibrosis in mice. We developed a triad of adeno-associated viruses that overexpressed microRNA-26a and microRNA-200a while inhibiting microRNA-21a to target hyperglycolysis and fibrotic signaling. Intraperitoneal injection of the viral triad inhibited the development of peritoneal fibrosis induced by PD fluid in mice. We conclude that hyperglycolysis is responsible for MMT and peritoneal fibrogenesis, and this aberrant metabolic state can be corrected by modulating microRNAs in the peritoneum. These results could provide a therapeutic strategy to combat peritoneal fibrosis.
20
MicroRNA-33 and the SREBP Host Genes Cooperate to Control Cholesterol Homeostasis
S. Hani Najafi‐Shoushtari, Fjoralba Kristo, Yingxia Li et al. · Science · 2010 · 938 citations
miR-200a Prevents Renal Fibrogenesis Through Repression of TGF-β2 Expression
Bo Wang, Philip Koh, Catherine E. Winbanks et al. · Diabetes · 2010 · 355 citations · Full text